Anebulo Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Anebulo Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q2 | 2026 | Dec 31, 2025 | ($2.00M) | Feb 12, 2026 |
| Q1 | 2026 | Sep 30, 2025 | ($2.16M) | Nov 13, 2025 |
| Q2 | 2026 | Sep 30, 2025 | ($2.16M) | Feb 12, 2026 |
| Q3 | 2025 | Mar 31, 2025 | ($1.68M) | May 13, 2025 |
| Q3 | 2025 | Dec 31, 2024 | ($2.46M) | May 13, 2025 |
| Q2 | 2026 | Dec 31, 2024 | ($2.46M) | Feb 12, 2026 |
| Q1 | 2026 | Sep 30, 2024 | ($2.20M) | Nov 13, 2025 |
| Q2 | 2026 | Sep 30, 2024 | ($2.20M) | Feb 12, 2026 |
| Q3 | 2025 | Sep 30, 2024 | ($2.20M) | May 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($1.65M) | May 13, 2025 |
| Q2 | 2025 | Dec 31, 2023 | ($2.72M) | Feb 14, 2025 |
| Q3 | 2025 | Dec 31, 2023 | ($2.72M) | May 13, 2025 |
| Q1 | 2025 | Sep 30, 2023 | ($2.48M) | Nov 13, 2024 |
| Q2 | 2025 | Sep 30, 2023 | ($2.48M) | Feb 14, 2025 |
| Q3 | 2025 | Sep 30, 2023 | ($2.48M) | May 13, 2025 |
| Q3 | 2024 | Mar 31, 2023 | ($2.80M) | May 15, 2024 |
| Q3 | 2024 | Dec 31, 2022 | ($3.83M) | May 15, 2024 |
| Q2 | 2024 | Dec 31, 2022 | ($3.83M) | Feb 13, 2024 |
| Q3 | 2024 | Sep 30, 2022 | ($2.61M) | May 15, 2024 |
| Q2 | 2024 | Sep 30, 2022 | ($2.61M) | Feb 13, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q2 | 2026 | Dec 31, 2025 | ($2.62M) | Feb 12, 2026 |
| Q1 | 2026 | Sep 30, 2025 | ($2.26M) | Nov 13, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($1.89M) | May 13, 2025 |
| Q2 | 2026 | Dec 31, 2024 | ($2.59M) | Feb 12, 2026 |
| Q1 | 2026 | Sep 30, 2024 | ($2.41M) | Nov 13, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($1.66M) | May 13, 2025 |
| Q2 | 2025 | Dec 31, 2023 | ($2.76M) | Feb 14, 2025 |
| Q1 | 2025 | Sep 30, 2023 | ($2.54M) | Nov 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($2.86M) | May 15, 2024 |
| Q2 | 2024 | Dec 31, 2022 | ($3.81M) | Feb 13, 2024 |
| Q1 | 2024 | Sep 30, 2022 | ($2.61M) | Nov 14, 2023 |
| Q3 | 2023 | Mar 31, 2022 | ($1.88M) | May 11, 2023 |
| Q2 | 2023 | Dec 31, 2021 | ($1.07M) | Feb 10, 2023 |
| Q1 | 2023 | Sep 30, 2021 | ($1.55M) | Nov 10, 2022 |
| Q3 | 2022 | Mar 31, 2021 | ($552.1K) | May 11, 2022 |
| Q2 | 2022 | Dec 31, 2020 | ($324.6K) | Feb 11, 2022 |